clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Conjunctival Neoplasms D003230 3 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ureteral Diseases D014515 3 associated lipids
IgA Deficiency D017098 2 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Soft Tissue Infections D018461 2 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Adamek RJ et al. Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection. 1995 Am. J. Gastroenterol. pmid:7801936
Jaup BH and Norrby A Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. 1995 Am. J. Gastroenterol. pmid:7771426
Gisbert JP et al. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? 2005 Am. J. Gastroenterol. pmid:16128936
Pamuk ON et al. Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? 2000 Am. J. Gastroenterol. pmid:10926000
Schaeverbeke T et al. Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. 2005 Am. J. Gastroenterol. pmid:16393213
de Bortoli N et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. 2007 Am. J. Gastroenterol. pmid:17313499
Mohar A et al. Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. 2002 Am. J. Gastroenterol. pmid:12385434
De Francesco V et al. Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia? 2002 Am. J. Gastroenterol. pmid:12385470
Chey WD and Wong BC American College of Gastroenterology guideline on the management of Helicobacter pylori infection. 2007 Am. J. Gastroenterol. pmid:17608775
Uygun A et al. Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. 1999 Am. J. Gastroenterol. pmid:10520880
Cremonini F et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. 2002 Am. J. Gastroenterol. pmid:12425542
Peterson WL et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. 1993 Am. J. Gastroenterol. pmid:8237933
Nista EC et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. 2006 Am. J. Gastroenterol. pmid:16968503
van Zanten SV and Thompson K Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? 2006 Am. J. Gastroenterol. pmid:16863548
Rokkas T et al. Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. 2006 Am. J. Gastroenterol. pmid:16928256
Watson JB and Moss SF Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. 2011 Am. J. Gastroenterol. pmid:22056576
Sapone A et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. 2003 Am. J. Gastroenterol. pmid:12809821
Zhou L et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. 2014 Am. J. Gastroenterol. pmid:24642580
Sharma VK et al. A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. 1999 Am. J. Gastroenterol. pmid:10566709
Gisbert JP et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. 2006 Am. J. Gastroenterol. pmid:16454825
Ali' A et al. A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. 1999 Am. J. Gastroenterol. pmid:10445583
Vakil N et al. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. 1998 Am. J. Gastroenterol. pmid:9732920
Chu KM et al. A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. 1998 Am. J. Gastroenterol. pmid:9732921
Lamouliatte H et al. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. 1998 Am. J. Gastroenterol. pmid:9732938
Hsu PI et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. 2005 Am. J. Gastroenterol. pmid:16279889
Vakil N Helicobacter pylori: factors affecting eradication and recurrence. 2005 Am. J. Gastroenterol. pmid:16279890
Sullivan B et al. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. 2002 Am. J. Gastroenterol. pmid:12385435
Gisbert JP et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. 2008 Am. J. Gastroenterol. pmid:17764498
Dohil R et al. Effective 2-wk therapy for Helicobacter pylori disease in children. 1997 Am. J. Gastroenterol. pmid:9040199
Lerang F et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? 1997 Am. J. Gastroenterol. pmid:9040200
Odaka T et al. Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. 2002 Am. J. Gastroenterol. pmid:11922552
Chey WD et al. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. 1997 Am. J. Gastroenterol. pmid:9317068
Ozmen MM and Johnson CD Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? 1995 Am. J. Gastroenterol. pmid:7661197
Savarino V et al. New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. 1995 Am. J. Gastroenterol. pmid:7717343
Trevisani L et al. A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. 1998 Am. J. Gastroenterol. pmid:9517646
Zullo A et al. Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. 1997 Am. J. Gastroenterol. pmid:9362185
Sirimontaporn N et al. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. 2010 Am. J. Gastroenterol. pmid:20010919
Basu PP et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. 2011 Am. J. Gastroenterol. pmid:21989146
Hasegawa T et al. Image of the month: Disseminated Nontuberculous Mycobacteriosis. 2015 Am. J. Gastroenterol. pmid:26673493
Schwartz H et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. 1998 Am. J. Gastroenterol. pmid:9576452
Vakil N Helicobacter pylori treatment: a practical approach. 2006 Am. J. Gastroenterol. pmid:16542285
Santander C et al. Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. 1996 Am. J. Gastroenterol. pmid:8759659
Tursi A et al. Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication. 1996 Am. J. Gastroenterol. pmid:8759696
Jarbol DE et al. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. 2006 Am. J. Gastroenterol. pmid:16771937
van der Wouden EJ et al. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. 1998 Am. J. Gastroenterol. pmid:9707042
Laine L et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. 2000 Am. J. Gastroenterol. pmid:11151867
Nakao K et al. Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. 1997 Am. J. Gastroenterol. pmid:9177520
Maconi G et al. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? 2001 Am. J. Gastroenterol. pmid:11232676
Parasakthi N and Goh KL Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia. 1995 Am. J. Gastroenterol. pmid:7872306
Chey WD et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. 2017 Am. J. Gastroenterol. pmid:28071659